CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

DisulfiramWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug2839 Tele-Yoga Therapy Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D059350 Chronic Pain NIH 0.35

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0012532 Chronic pain HPO 0.35

There is one clinical trial.

Clinical Trials

1 Virologic and Immunologic Response to Disulfiram in Early Symptomatic COVID+ Outpatients

Disulfiram a safe, easily dosed, FDA-approved drug for the treatment of alcohol dependence has been identified to be a potential therapeutic target for SARS-CoV-2 infection. Disulfiram may have both antiviral (inhibiting viral replication via blocking the Mpro protease and zinc ejection) and anti-inflammatory effects (via inhibition of NF-kB-induced and NLRP inflammasome-induced cytokine release) on SARS-CoV-2. We will test disulfiram 2000 mg/day for 3 consecutive days (doses shown to be well tolerated and safe in a recent phase 2b trial) in 60 symptomatic COVID PCR+ individuals in a randomized (1:1) clinical trial evaluating the effect on COVID symptoms severity, SARS-CoV-2 viral load, and biomarkers of inflammation over 31 days.

NCT04485130 Covid19 Drug: Disulfiram Drug: Placebo

Primary Outcomes

Description: The safety and tolerability of a 3 day course of disulfiram. The number of adverse events and their grade will be determined for each participant.

Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time: 31 days

Description: The severity of COVID-19 symptoms will be recorded on a 5-point symptom severity scale at each visit for each participant.

Measure: Change in COVID-19 symptom severity score as assessed by a 5-point adapted somatic symptom severity score (SSS-8)

Time: 31 days

Secondary Outcomes

Description: Quantitative SARS-CoV-2 viral load measures will be determined at each visit for each participant.

Measure: Virologic impact of 3 days of disulfiram, as measured by the fold-change in copies of SARS-CoV-2 virus per million cells between Baseline and Day 31.

Time: 31 days

Description: High sensitivity plasma cytokine measures for interleukin 6, interleukin 1-beta, and other pro-inflammatory cytokines will be determined at each visit for each participant.

Measure: Immunologic impact of 3 days of disulfiram, as measured by the fold-change in plasma levels of pro-inflammatory cytokines (e.g, interleukin 6, interleukin 1-beta, etc.).

Time: 31 days

No related HPO nodes (Using clinical trials)